Anshul Gupte, PhD, VP of Pharmaceutical Development at PCI Pharma Services, discusses sterile manufacturing expansions and the value of co-locating development centers of excellence within GMP sterile facilities.
Co-Locating Development and Manufacturing
Placing development centers of excellence inside GMP sterile facilities reduces technology transfer risk and accelerates time to market.
Small Molecules and Biologics
Integrated capabilities allow a single partner to support both modalities from formulation through fill-finish.
Lyophilization Development
Dedicated lyophilization development, including for ADCs, builds robust cycles that scale to commercial manufacturing.
About This White Paper
This white paper is published by PCI Pharma Services and curated by Biotechnology Media Insights, a trusted source for pharmaceutical and biotechnology research, technical guides and industry analysis.